Changeflow GovPing Pharma & Drug Safety EPO Patent: Composition for Controlling Bacteri...
Routine Guidance Added Final

EPO Patent: Composition for Controlling Bacterium Proliferation in Intestine

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Pharma (A61K)
Published March 18th, 2026
Detected March 24th, 2026
Email

Summary

The European Patent Office has published patent application EP4494483A1 for a composition designed to control bacterium proliferation in the intestine. The patent, assigned to MEIJI CO., LTD, details specific uses and classifications related to pharmaceutical and food science applications.

What changed

The European Patent Office (EPO) has published patent application EP4494483A1, titled "Composition for controlling bacterium proliferation in intestine, and use thereof." This application, filed by MEIJI CO., LTD, outlines a novel composition and its applications, primarily focusing on pharmaceutical and food science aspects related to intestinal health.

This publication represents a new patent filing and does not impose immediate compliance obligations. However, companies operating in the pharmaceutical and food manufacturing sectors, particularly those involved in developing products for gut health or microbiome modulation, should be aware of this patent. It may influence future product development, research, and intellectual property strategies within the European Union.

Source document (simplified)

← EPO Patent Bulletin

COMPOSITION FOR CONTROLLING PROLIFERATION OF BACTERIUM IN INTESTINE, AND USE THEREOF

Publication EP4494483A1 Kind: A1 Mar 18, 2026

Applicants

MEIJI CO., LTD

Inventors

FUJIWARA Shin, TAKEDA Mariko

IPC Classifications

A23L 33/125 20160101AFI20241218BHEP A23L 33/10 20160101ALI20241218BHEP A23L 33/135 20160101ALI20241218BHEP A61K 31/7004 20060101ALI20241218BHEP A61K 31/7008 20060101ALI20241218BHEP A61K 31/7012 20060101ALI20241218BHEP A61K 31/7016 20060101ALI20241218BHEP A61K 31/702 20060101ALI20241218BHEP A61K 35/20 20060101ALI20241218BHEP A61P 1/00 20060101ALI20241218BHEP A61P 1/04 20060101ALI20241218BHEP A61P 1/12 20060101ALI20241218BHEP A61P 1/14 20060101ALI20241218BHEP A61P 1/16 20060101ALI20241218BHEP A61P 3/00 20060101ALI20241218BHEP A61P 9/06 20060101ALI20241218BHEP A61P 11/06 20060101ALI20241218BHEP A61P 13/12 20060101ALI20241218BHEP A61P 17/00 20060101ALI20241218BHEP A61P 25/00 20060101ALI20241218BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

Composition for controlling bacterium proliferation in intestine, and use thereof

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 18th, 2026
Instrument
Guidance
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4494483A1

Who this affects

Applies to
Drug manufacturers Food manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3114 Food & Beverage Manufacturing
Activity scope
Drug Development Food Product Development
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Product Development
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Food Safety Public Health

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.